Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong. The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming years.

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two compounding pharmacies that were selling copycat Zepbound and Mounjaro.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Learn more about LLY stock here.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its only real competitor in the field, Novo Nordisk.

Eli Lilly and Company (LLY) said on Monday that the highest approved doses of its weight-loss drug Zepbound will soon be available on its digital health platform LillyDirect. The 12.5 mg and 15 mg doses will be available in single-dose vials and priced at $499 per month for self-paying customers,

Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound. | With the move, all of Eli Lilly's Zepbound doses will soon be available in cheaper single-dose vials for $499 per month or less.